Introduction
Acute lung injury (ALI) is a major clinical problem in the United States with an estimated incidence rate of 262,500 patients and 40-50% mortality [1] [2] [3] . In experimental animals, detrimental effects of hyperoxia manifest as ALI. Hyperoxia therapy is a necessary part of treatment for patients with acute and chronic cardiovascular and pulmonary diseases [4] [5] [6] [7] [8] . However, prolonged exposure to hyperoxia may lead to ALI. ALI is characterized by severe alveolar damage resulting from an acute inflammatory response that leads to immune cell infiltration and edema [9, 10] . The fundamental mechanism of this serious condition evolves from an imbalance between proinflammatory and anti-inflammatory cytokines, and the simultaneous induction of apoptosis activators [1, 2, 11] . Hence, a viable approach to prevent ALI would be to resolve this imbalance. It is known that cytokine signaling is mediated via the Janus kinasessignal transducer and activator of transcription (JAK-STAT) signaling pathway, an important contributor to the production of inflammatory cytokines [12] . The suppressor of cytokine signaling-1 (SOCS-1) protein is a physiological regulator of cytokine production and has been shown to be the most efficient inhibitor of the JAK-STAT pathway [13] .
SOCS-1 is an antiapoptotic and potent anti-inflammatory, negative regulator of the IL-6-mediated JAK-STAT signaling pathway [14, 15] . It has also been reported that SOCS-1 exerts its protective effects against apoptosis induced by TNF-α, INF-γ, and LPS [16] [17] [18] [19] [20] [21] . Our recent report suggests that IL-6 cytoprotection against hyperoxic acute lung injury (HALI) is associated with enhanced SOCS-1 expression [4] . However, the therapeutic role of SOCS-1 under oxidative stress is not yet known.
Apoptosis signal-regulating kinase-1 (ASK-1) is one of the key mitogen-activated protein kinases (MAPKs) required for reactive oxygen species (ROS) and TNF-α induced cell death and inflammation [21] . Recent studies suggest the possibility that inhibitors of ASK-1 have potential benefits in the management of ALI [22] [23] [24] [25] and suggest that ASK-1 is significantly activated and involved in HALI [4] . The presented evidence indicates that Ad-SOCS-1 can protect against hyperoxic injury and is associated in the suppression of ASK-1.
Materials and methods

Reagents and antibodies
The following antibodies were used: SOCS-1 (Immuno-Biological Laboratories, Minneapolis, MN), GAPDH (Cell Signaling Technology, Inc., Beverly, MA), ASK-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and caspase-3 (Cell Signaling Technology, Inc., Beverly, MA). The protein concentration of cell lysates was quantified using a BCA assay kit (Thermo scientific, Rockford, IL). The SOCS-1 adenovirus (Ad-SOCS-1) and GFP adenovirus (Ad-GFP) were gifts kindly provided by Dr. Akihiko Yoshimura (Japan). All other reagents were purchased from Sigma (St. Louis, MO).
Mice
The approval of these animal procedures was obtained from the University of South Florida Institutional Animal Care and Use Committee (IACUC) and all mice were maintained in a specific-pathogenfree animal facility at the University of South Florida. C57BL/6J (wild type, 6 weeks old, 50% male, and 50% female; n¼ 20) mice were purchased from Harlan Laboratories (Indianapolis, IN).
Transfection protocols
Cells were treated with phosphate buffered saline (PBS), Ad-GFP, or Ad-SOCS-1 as noted previously [26] . After reaching confluence, cells were transduced with adenoviral stock containing 10 8 plaque forming units (PFU) according to the manufacturer's protocol (Millipore, Billerica, MA). Within 10-13 days, this treatment yielded greater than 95% of stable transductants. Adenoviral vectors were used to attain in vivo stable transduction of mice. C57BL/6 mice were intraperitoneally anesthetized with a ketamine/xylazine mixture. Prior to injection, the ventral area of the neck was sprayed with alcohol. A small incision was made in the ventral neck skin area to expose the trachea of each mouse. The adenovirus (10 8 PFU) in 50 ml of PBS was injected into the trachea. The incision was closed with wound closures and the mice were monitored until they recovered from anesthesia. Infected animals were maintained in separate cages for 72 h before hyperoxic exposure. Experimental groups Ad-SOCS-1 (n¼20), Ad-GFP (n¼20), and control group PBS (n¼ 20) were studied.
Hyperoxia exposure
Six-week-old mice (n ¼20) were placed in cages in a chamber (75 Â 50 Â 50 cm) and exposed to 100% O 2 for 72 h. The controls were exposed to room air. Concentration of O 2 in the chamber was regulated and monitored with a proOx P100 sensor (BioSpherix) as previously described [2] [3] [4] .
Bronchoalveolar lavage fluid collection
Mice were anesthetized with an intraperitoneal injection of ketamine/xylazine mixture. After cervical dislocation, the trachea was surgically exposed in the ventral neck area, and a 0.6 mm catheter was inserted into the trachea through a small incision [2, 5, 27] . Bronchoalveolar lavage (BAL) fluid was collected by perfusing the lungs with sterile PBS as previously described [27] .
The BAL fluid perfusion was repeated three times for each mouse. The cell-free BAL fluid was stored at À 80 1C until analysis.
Lung perfusion and tissue collection
After BAL fluid collection, the abdominal cavity was opened and lungs were perfused through the right ventricle using 10% formalin in PBS at pH 7.40. The left lobe of the lung was fixed in 0.5 ml of 10% neutral buffered formalin; then it was separated from the cavity for histological processing and paraffin embedding (FFPE) [2, 5, 27] . The remaining pieces of lungs were stored at À 80 1C until analysis. The paraffin-embedded lung tissue sections were stained with hematoxylin and eosin to evaluate the extent of lung injury.
ELISA
Levels of IL-1β (eBioscience, San Diego, CA), IL-6 (BD Bioscience, San Diego, CA), TNF-α (RayBiotech Inc., Norcross, GA), and MCP-1 (eBioscience, San Diego, CA) in BAL fluid were measured using commercial ELISA kits as per the manufacturer's instructions.
Lung injury evaluation
To quantitatively examine lung edema, we recorded wet/dry weight ratios by removing six lungs per group from the hilum as previously described [28] . The lungs were dry blotted and weighed to determine the wet weight. Then the lungs were desiccated overnight by 130 1C incubation in a vacuum oven and reweighted to obtain the dry weight. We then calculated the wet/dry ratio [28] . The remaining portions of the lungs were dissected out carefully, frozen in liquid nitrogen, and stored at À 80 1C until analysis.
Alveolar fluid clearance (AFC)
AFC was measured as previously described [29] AFC was calculated by:
where V i represents the volume of injected albumin solution and V f represents the volume of the final alveolar fluid and E represents the (E i ) injected and (E f ) final concentrations of the Evans Blue-labeled 5% albumin solution.
Survival study
Mice treated with Ad-SOCS-1 (n ¼20) or Ad-GFP (n¼ 20) were exposed to continuous 100% O 2 exposure (hyperoxia) for evaluation of survival. The number of surviving mice was determined at 24-h intervals until the last mouse died.
Analysis of BAL fluid
Entire BAL fluid ( $2-3 ml) was centrifuged at 200g for 10 min at 4 1C. The supernatants were stored at À 80 1C until analysis, and the cell pellets were resuspended with ice-cold sterile PBS (1 ml). The total number of cells in cell suspension was counted using a glass hemocytometer. Aliquots of 100-300 μl of each cell suspension were centrifuged onto glass slides at 800 rpm for 3 min in a cytocentrifuge (Shandon Cytospin 2, Pittsburgh, PA). Cytospinned cells were stained with Diff-Quik stain set (Andwin Scientific, Schaumburg, IL) and differential white blood cell count was performed on a minimum of 200 cells under a microscope at 200 Â magnification [27] .
Immunocytochemical staining
Cells in 35 mm dishes were fixed with 4% paraformaldehyde for 5 min and permeabilized with 1% Triton X-100 in PBS for 10 min. They were then incubated with primary antibodies overnight and probed with fluorescent conjugated secondary antibody for 2 h. After repeated washing, cells were air dried and Hoechst stain containing mounting medium was used to mount the slides. The slides were viewed with an Olympus IX81 inverted microscope fitted with the 3i Yokogawa spinning disk scanner and CCD cameras with revolving laser arrays.
Real-time PCR
Total RNA was isolated from mouse lung lysates and alveolar macrophages using Trizol according to the manufacturer's protocols (QIAGEN, Valencia, CA). Total RNA was used for cDNA synthesis by iScript cDNA synthesis kit (BioRad Laboratories, Hercules, CA) according to the manufacturer's recommendations. Quantitative PCR was performed by using a BioRad iCycler with SYBR green supermix (BioRad Laboratories, Hercules, CA) and ribonucleasefree water. qRT-PCRs were performed using the following conditions: amplification at 95 1C for 3 min followed by 40 cycles at 95 1C for 15 s and 60 1C for 30 s. The mRNA expression of Ad-SOCS-1 was measured using specific primers: (forward) 5 0 -TCC GTT CGC ACG CCG ATT AC-3 0 and (reverse) 5 0 -TCA AAT CTG GAA GGG GAA GG-3 0 . Fluorescence readings determined the amount of amplification at the end of each cycle. 18S rRNA ribosomal peak intensity was used to assess the RNA quality and the ΔC T method was used to estimate the relative amount of RNA in sample.
Western blot
Equal amount of protein was prepared for SDS-PAGE; and protein was transferred to a polyvinylidene difluoride membrane by following the electrophoresis method noted in study [30] . The membrane was blocked in 5% nonfat dry milk in PBS containing 0.05% Tween 20 (PBS/T) for 1 h at room temperature. Primary and secondary antibodies were diluted to 1000-fold in PBS/T with 2.5% nonfat milk. Probing with antibodies and washing steps on the membrane were followed as previously noted [30] . A Pierce ECL Western blotting substrate kit (Thermo scientific Rockford, IL, USA) was utilized to detect the protein as per the manufacturer's instructions and exposed in a ChemiDoc XRS (Biorad, Hercules, CA, USA).
Statistics
In survival experiments, n equals 20 in each group. Values are expressed as means 7 SE. Statistical significance was assessed by using GraphPad Prism version 10.00 for Windows (GraphPad Software, San Diego, CA). Group differences were determined using one-and two-way ANOVA or Student's unpaired t test. P o0.05 was considered statistically significant. Kaplan-Meier analysis was utilized for survival analysis and survival differences between groups were assessed using ψ2 analysis.
Results
In vivo Ad-SOCS-1 treatment and lung distribution of Ad-SOCS-1
Each mouse (n¼ 20) was intratracheally treated with 10 8 PFU of recombinant Ad-SOCS-1 or Ad-GFP and allowed to recover for 72 h. As a first step, we confirmed the adenoviral gene delivery and transfection by immunocytochemical staining for SOCS-1 in lungs and protein expression of Ad-SOCS-1 in lung lysates and alveolar macrophages (AM). Immunocytochemistry confirms that Ad-SOCS-1 reached the lung parenchyma and was distributed throughout the lung including the small distal airways and alveolar region (proximal and distal) (Fig. 1A) . Western blot analysis of Ad-SOCS-1 in lung lysates and AM showed a significant increase in Ad-SOCS-1 protein expression compared to the Ad-GFP-transfected controls (Fig. 1B) . Adenoviral transfection was further verified by using real-time PCR analysis of lung lysates and AM (Fig. 1C) . The mRNA expression of Ad-SOCS-1 was higher in the lung and AM isolates obtained from mice transfected with adenovirus carrying the recombinant SOCS-1 compared to their littermate controls. The presence of Ad-SOCS-1 was detected in airway epithelium (44%), alveolar epithelial cells (22.1%), and macrophages (33.9%) of total immunopositive cells. These results suggest that the adenoviral-mediated gene delivery of recombinant SOCS-1 was efficient.
Supplementation of mice with Ad-SOCS-1 dampens hyperoxia-induced ALI
To check if Ad-SOCS-1 can induce protection against hyperoxiainduced ALI, we administered mice with Ad-SOCS-1 or Ad-GFP (control) and exposed mice to hyperoxia for 72 h. We then analyzed lung morphology by H&E staining (Fig. 2) . The results demonstrated a significant infiltration of immune cells and damage in alveoli in untreated or Ad-GFP-treated mice when compared to Ad-SOCS-1-treated mice. Further, gross examination of lungs in the Ad-GFP-administered mice was observed to be hemorrhagic and marshy with edema fluid upon dissection of the trachea. In contrast, these changes were suppressed and unchanged from baseline in lungs of Ad-SOCS-1-administered mice. These results suggest that administration of Ad-SOCS-1 attenuates hyperoxia-induced ALI and confers protection in mice exposed to hyperoxia.
Increased survival rates in hyperoxia-exposed mice treated with Ad-SOCS-1
We checked whether Ad-SOCS-1 can induce extended survival rates in mice exposed to hyperoxia and analyzed the rate of survival. Ad-SOCS-1-administered mice exposed to 100% oxygen showed enhanced survival compared to Ad-GFP control mice. After 3 days of hyperoxia, Ad-GFP mice were ill and were manifested by tachypnea. In contrast, all Ad-SOCS-1-treated mice survived for at least 6 days in hyperoxia and 80% of them survived even beyond 7 days (Fig. 3) . Interestingly, Ad-SOCS-1 mice exhibited normal levels of activity and normal respiratory rate throughout their hyperoxic exposure. These results confirmed that Ad-SOCS-1 expression prolonged survival rate in mice exposed to hyperoxia.
Hyperoxia-induced immune cell accumulation was suppressed in mice administered with Ad-SOCS-1
We exposed mice to hyperoxia for 72 h post administration with Ad-SOCS-1 or the control Ad-GFP. BALF was extracted from these mice and was analyzed for total cells, macrophages, and neutrophils. Quantification of total cells from BAL fluid is suitable for assessing alveolitis in hyperoxia-induced murine models. Our results showed a significant decrease in the total number of cells in mice treated with Ad-SOCS-1 when compared to mice administered with Ad-GFP. No significant difference was found between the two groups of mice (Ad-SOCS-1 and Ad-GFP) under normoxic conditions (Fig. 4A) . Neutrophil infiltration and macrophage accumulation of the pulmonary interstitium and alveoli are known to be main features of ALI. Macrophage counts were significantly low in mice that received Ad-SOCS-1 compared to mice with Ad-GFP under hyperoxia. Total amount of macrophages remained the same in both groups of mice under room air (Fig. 4B) . We then evaluated neutrophil infiltration in mice that received Ad-SOCS-1 or control Ad-GFP exposed to hyperoxia. Neutrophil accumulation was significantly decreased in mice that received Ad-SOCS-1 compared to Ad-GFP controls. Total number of neutrophils remained the same in mice (Ad-SOCS-1 and Ad-GFP) exposed to normoxia (Fig. 4C) . Taken together, these results suggest that SOCS-1 plays a key role in immune cell accumulation and infiltration in hyperoxia-induced ALI.
Hyperoxia-mediated lung edema and alveolar leak were suppressed in Ad-SOCS-1-treated mice Development of pulmonary edema and protein leak in the alveoli are hallmarks of ALI that ultimately end in respiratory failure. We analyzed total protein content in mice treated with Ad-SOCS-1 or Ad-GFP under normoxia and hyperoxia. Our results indicated a significant drop in the total protein content in mice treated with Ad-SOCS-1 exposed to hyperoxia when compared with Ad-GFP controls. No significant difference was found in the protein levels when both groups were exposed to room air (Fig. 5A) . We assessed lung edema by obtaining wet/dry ratios in mice administered with Ad-SOCS-1 or Ad-GFP under hyperoxia and room air. Wet/dry ratio levels were significantly lower in mice that received Ad-SOCS-1 when compared to mice administered with Ad-GFP under hyperoxia. Lung edema content remained the same in both groups exposed to room air (Fig. 5B) . These results indicate that Ad-SOCS-1 suppresses lung edema formation and alveolar leak.
Ad-SOCS-1-induced alveolar fluid clearance in mice exposed to hyperoxia
Since our results showed that Ad-SOCS-1 mediated protection against ALI and was associated with reduced lung edema (wet/dry ratio), we further analyzed whether Ad-SOCS-1 is involved in alveolar fluid transport in hyperoxia-induced ALI. Mice were administered with Ad-SOCS-1 or control Ad-GFP. mice compared to their Ad-GFP controls under hyperoxia (Fig. 5C ). These results suggest that Ad-SOCS-1 restores alveolar fluid clearance in hyperoxia-induced ALI.
Ad-SOCS-1 administration reduces inflammatory cytokines in BAL in mice exposed to hyperoxia IL-1β is one of the most robust cytokines in the lungs of ALI patients. Secretion of IL-1β can further trigger a cytokine storm worsening the inflammatory response. We checked the levels of IL-1β in BALF of mice exposed to room air and hyperoxia that were pretreated with Ad-SOCS-1 or Ad-GFP. Results show that IL-1β was significantly suppressed in BALF of mice that received Ad-SOCS-1 compared to control mice under hyperoxia. No IL-1β induction was observed when mice were exposed to room air (Fig. 6A) . Additionally, we also measured the levels of another proinflammatory cytokine IL-6. Ad-SOCS-1-treated mice showed significantly low levels of IL-6 compared to their Ad-GFP controls under hyperoxia. No such difference was observed when mice were exposed to room air (Fig. 6B) . TNF-α is the most well-known proinflammatory cytokine member of the TNF family and is recognized as a mediator of the inflammatory response in the lungs. Levels of TNF-α in BAL fluid obtained from Ad-SOCS-1-treated mice and Ad-GFP-treated mice exposed to 100% O 2 for 72 h and room air were evaluated. Results show that hyperoxia-induced TNF-α elevation was significantly suppressed in mice that received Ad-SOCS-1 compared to their Ad-GFP controls (Fig. 6C) . However, no such difference was observed in mice exposed to room air. MCP-1 is known to be a potent chemoattractant on monocytes/macrophages. MCP-1 concentrations in BAL fluid obtained from Ad-SOCS-1-treated mice and Ad-GFPtreated mice exposed to hyperoxia and room air were evaluated. MCP-1 levels were significantly low in mice treated with Ad-SOCS-1 compared to controls when mice were exposed to 100% oxygen for 72 h. No such differences were found in mice exposed to room air (Fig. 6D) . These results suggest that Ad-SOCS-1 diminishes the secretion of hyperoxia-induced proinflammatory cytokines such as IL-1β, IL-6, TNF-α, and MCP-1.
Ad-SOCS-1-mediated protection in ALI may be due to suppression of ASK-1
It has been shown that SOCS-1 protects against TNF-α-induced and ASK-1-mediated cell death. Thus, we hypothesized that the protective effects of Ad-SOCS-1 mice could be in part due to its ability to suppress this ASK-1-mediated apoptotic response. We analyzed the levels of ASK-1 and caspase-3 expression by immunoblot analysis. Our results showed a significant decrease in ASK-1 protein expression in mice lysates treated with Ad-SOCS-1 when compared to Ad-GFP controls under hyperoxia (Fig. 7) . Further, we checked for the expression levels of total caspase-3 and cleaved caspase-3 in these lysates and our results strongly supported our hypothesis, indicating that ASK-1 protein expression is significantly inhibited in the Ad-SOCS-1 mice even in room air and hyperoxia which is further associated with a significant decrease in cleaved caspase-3 when compared to Ad-GFP control mice.
Discussion
The purpose of this study was to investigate whether direct overexpression of Ad-SOCS-1 could provide protection from lethal hyperoxia. The present study shows that (i) Ad-SOCS treatment attenuates hyperoxia-induced ALI and confers protection to mice exposed to hyperoxia; (ii) Ad-SOCS-1-treated mice shows extended survival when compared to Ad-GFP-treated mice; (iii) hyperoxia-induced immune cell infiltration was suppressed in mice administered with Ad-SOCS-1; (iv) Ad-SOCS-1 administration suppressed hyperoxia-induced infiltration of inflammatory cytokines; (v) Ad-SOCS-1 administration also suppressed hyperoxia-mediated lung edema, and alveolar leak; (vi) Ad-SOCS-1 administration restores alveolar fluid clearance; (vii) Ad-SOCS-1-mediated protection is associated with the suppressed ASK-1 protein expression.
Tracheal instillation was used as the choice of delivery over vascular administration since it is potentially appropriate to clinical local gene therapy for the lung. Based on the staining, our method using adenoviral delivery of SOCS-1 locally to the lung showed that it reaches to the epithelium and sufficient to protect from hyperoxic injury. It has also been demonstrated that intratracheal transduction of iNOS adenovirus decreases vasoconstrictor responses in rats [31] . In addition, staining of lungs of iNOStransfected animals showed transgenic expression in the alveolar wall cells [31] .
Several in vitro and in vivo studies demonstrated that SOCS-1 plays as an antiapoptotic and anti-inflammatory molecule in immunological disorders [14, 15] . It has been shown that SOCS-1 plays an important role in protecting against Chlamydia pneumonia-induced lethal inflammation but hinders effective clearance of the bacteria [32] . SOCS-1-deficient mice die within 3 weeks of birth with severe inflammation and lung damage through infiltration of inflammatory cells [15] [16] [17] [18] [19] , which is strikingly similar to the clinical manifestation of ALI. It has also been documented that intracellular protein therapy with SOCS-3 inhibits inflammation and apoptosis [20] . Previously, our studies showed that SOCS-1 overexpression protects from H 2 O 2 -induced cell death [4] . In continuation to these studies, the therapeutic role of SOCS-1 overexpression against lethal hyperoxia is demonstrated in the present investigation.
It is known that persistent hyperoxic exposure can lead to ALI and result in inflammation and alveolar damage [10] , which is consistent with our results. Based on our histological evaluation, lung tissue exposed to hyperoxia showed extreme change to the alveoli with many hemorrhagic sites of edema in Ad-GFP control mice. However, these changes were significantly ameliorated in mice administered with SOCS-1. Our observations suggest that hyperoxia modulates the inflammatory pathways in the lung and SOCS-1 suppresses these changes as evident in our results of suppressed infiltration of immune cells and cytokines. In addition, mice expressing the Ad-SOCS-1 gene have enhanced survival in 100% hyperoxia and showed normal levels of activity and normal respiratory rate. Although no Ad-GFP mice remained by the sixth day, 80% of Ad-SOCS-1 mice still survived by the seventh day. This extended survival may be the result of the suppressed infiltration of immune cells and alveolar damage as seen in Ad-SOCS-1 mice.
SOCS-1 has been shown to inhibit JAK kinase activity and suppresses infiltration of monocytes and neutrophils [33] . Neutrophils and macrophages are important components of the inflammatory responses that characterize ALI. Flooding of neutrophils into the bronchoalveolar space can be associated with endothelial and epithelial injury as well as lung edema [34] . Neutrophils are a major factor in the development of ALI and ARDS since neutrophil activation and transmigration are key effects in the development of ALI and ARDS [34] . In experimental models, the elimination of neutrophils significantly decreases the severity of ALI [35] . In the present study, our BAL fluid analysis reveals a significant decrease in total cells, macrophages, and neutrophils in Ad-SOCS-1-administered mice exposed to hyperoxia when compared to control mice. These results suggest that SOCS-1 is associated with the regulation of immune cell accumulation and infiltration in oxygen toxicity.
It is well established that IL-6 plays an important role in the pathophysiology of acute lung injury [36] and patients with ALI were found to have high plasma IL-6 levels [37] . In our study, Ad-SOCS-1-related mice had significantly reduced IL-6 levels in BAL fluid. This suggests that SOCS-1 has protective effects in part due to attenuated IL-6 levels. In addition, levels of MCP-1, which is known to play a key part in selectively recruiting cytokines such as neutrophils and monocytes [38] , were significantly reduced in BAL fluid of Ad-SOCS-1-administered mice. This suggests that SOCS-1 suppresses infiltration of cytokines which help inhibit infiltration of inflammatory cytokines. It is recognized that air exchange between the circulatory system and the alveolar space is important for respiration [39] . In ALI, failure of the lung epithelial barrier leads to airspace flooding, significantly decreasing the efficiency of gas exchange that exacerbates the severity of ALI. In addition, earlier studies demonstrated that resolution of pulmonary edema and lung inflammation is important in the recovery from ALI [40] . Accordingly, our results indicate that Ad-SOCS-1 suppresses lung edema formation and alveolar leak exposed to hyperoxia. This suggests that SOCS-1 protects against alveolar cell damage which eliminates leaking into the airspace.
Earlier studies suggested that patients with maximal alveolar fluid clearance have a lower mortality in ALI [41] . Our study for the first time shows that administration of Ad-SOCS-1 significantly clears the alveolar fluid in the lungs of mice exposed to hyperoxia. These results suggest that SOCS-1 not only inhibits leaking but also returns alveolar clearance to its normal state.
Previous clinical studies reveal that inflammatory cytokines and chemokines work together in mediating, amplifying, and perpetuating the process of lung injury [42] . Moreover, inflammatory cytokines like IL-1β can induce the production of other chemotactic cytokines like IL-8. The cytokine IL-1β is also suppressed by SOCS-1 [43] . Our data show that overexpression of Ad-SOCS-1 can significantly inhibit the production of proinflammatory cytokines including IL-1β in BALF of mice exposed to oxygen toxicity.
Recent studies show that tolerance of LPS is decreased in SOCS-1 À / À cells [44] . SOCS-1-deficient cells have impaired endotoxin tolerance [44] . However, in our previous studies we showed that epithelial cells exposed to H 2 O 2 (which induce oxidative stress) are unable to induce SOCS-1 protein expression levels [4] . Either hyperoxia exposure or H 2 O 2 exposure causes significant ASK-1 activation [4] . Further previous studies revealed that ASK-1 IL-6 levels in BALF (pg/ml) **
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Ad-GFP Ad-SOCS-1 Ad-GFP Ad-SOCS-1 Fig. 6 . Ad-SOCS-1 administration reduces inflammatory cytokines in BAL in mice exposed to hyperoxia. Male and female C57Bl/6 mice transfected with recombinant Ad-SOCS-1 and Ad-GFP were exposed to room air (normoxia) or 100% O 2 (hyperoxia) at 72 h as described under Materials and methods. Proinflammatory cytokine levels (A) IL-1β, (B) IL-6, (C) TNF-α, and (D) MCP-1 of SOCS-1-and GFP-treated mice under normoxic and hyperoxic conditions were analyzed using ELISA. **P o 0.01 when compared between Ad-GFP-and Ad-SOCS-1-transfected mice under hyperoxia. IB: GAPDH --+ + Fig. 7 . Ad-SOCS-1-mediated protection in ALI may be due to suppression of ASK-1. Male and female C57Bl/6 mice transfected with recombinant Ad-SOCS-1 and Ad-GFP were exposed to room air (normoxia) or 100% O 2 (hyperoxia) at 72 h as described under Materials and methods. Western blot analysis of ASK-1 and caspase-3 (total and cleaved) from cell lysates was obtained from Ad-SOCS-1-or Ad-GFP-treated cells under hyperoxic or normoxic conditions. GAPDH was used as an internal control. Data are representative of at least 3 independent experiments.
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regulates both apoptosis and inflammation [45, 46] . According to these findings, we examined if ASK-1 levels changed in Ad-SOCS-1-overexpressed mice compared to control. Our results indicate that ASK-1 levels were significantly suppressed in Ad-SOCS-1-overexpressed mice exposed to hyperoxia compared to controls. These results are further supported by significant decrease in cleaved caspase-3. These results suggest that SOCS-1 can protect cell death in part by suppressing ASK-1-mediated apoptosis. This is supported by our previous study as we documented that the mechanism of SOCS-1-mediated protection against ROS-induced cell death in vitro occurs through ASK-1 degradation [4] .
Since oxidative injury is a key element in the pathogenesis of a wide variety of pulmonary diseases and disorders, the present findings are significant from this severe oxidative stress animal model because we showed that SOCS-1 is able to protect from this severe oxidative stress-induced ALI model. Our studies demonstrate, for the first time, that the protective effects of SOCS-1 in the setting of HALI are associated with a significant decrease in inflammation and apoptosis. Our data suggest that SOCS-1 is protective against oxidant-induced injury via ASK-1 degradation. Since oxidative stress plays a critical role in the pathogenesis of many other diseases, the role of SOCS-1 in our model will offer clues to its role in other oxidative stress-related diseases.
In summary, we demonstrate for the first time that adenovirusmediated SOCS-1 overexpression in mice lungs significantly protects from hyperoxic lung injury when compared to a control adenovirus. Decreased damage is seen by suppressed permeability of alveolar epithelium and inhibition of immune cell accumulation. SOCS-1 protection against ALI is further supported by ASK-1 suppression under Ad-SOCS-1 treatment. These findings reveal that SOCS-1 may have great protective effects against lethal oxidant lung injury. Clinically, the overexpression of SOCS-1 may be a novel approach for suppressing ALI and ASK-1-mediated inflammatory diseases.
